Proteasome inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Proteasome Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Proteasome Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Proteasome Inhibitors: Overview
Proteasomes play a necessary role in cell survival, DNA repair and the proliferation of malignant cells. Proteasomes also play an active role in normal cellular functions, and in the degradation of misfolded or mutated proteins. The mechanism by which Proteasome Inhibitors lead to cell death is diverse and affects many pathways utilized in cancer cells. One putative mechanism of cytotoxicity is inhibition of the NF-kB pathway, a pro-survival pathway for many cell types, especially those of hematopoetic lineages.
Multiple putative mechanisms of cellular toxicity have been proposed for Proteasome Inhibitors (PIs). Included amongst these is direct induction of apoptosis through c-Jun NH2-terminal kinase (JNK) and p53. The expression of p53, a known tumor-suppressor important in activating cell death under diverse circumstances, is induced by treatment with PIs, which can induce apoptosis even in the presence of mutant p53.
Since Proteasome Inhibitors have been impressively effective in the treatment of hematologic malignancies, they continue to be an area of interest for new indications and to improve existing PI regimens. Clinical trials of PIs in combination with other agents are being conducted in leukemias, lymphomas, solid tumors and GVHD. PIs continue to be developed that might target the proteasome at different sites to overcome resistance or have activity in different malignancies. Areas of resistance include hyperactivation of the trypsin-like (?2) and caspase-like (?1) proteolytic sites to compensate for inactivation at the chymotrypsin-like (?5) site. Proteasome Inhibitors target cellular mechanisms of protein degradation by blocking the ? proteolytic subunits of the 20s proteasome.
Report Highlights
This segment of the Proteasome Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Proteasome Inhibitors Emerging Drugs
It is currently in Phase III stage of development and is being developed by Celgene.
Further product details are provided in the report……..
Proteasome Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Proteasome Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Proteasome Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Proteasome Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Proteasome Inhibitors drugs.
Proteasome Inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Proteasome Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Proteasome Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Proteasome Inhibitors: Overview
Proteasomes play a necessary role in cell survival, DNA repair and the proliferation of malignant cells. Proteasomes also play an active role in normal cellular functions, and in the degradation of misfolded or mutated proteins. The mechanism by which Proteasome Inhibitors lead to cell death is diverse and affects many pathways utilized in cancer cells. One putative mechanism of cytotoxicity is inhibition of the NF-kB pathway, a pro-survival pathway for many cell types, especially those of hematopoetic lineages.
Multiple putative mechanisms of cellular toxicity have been proposed for Proteasome Inhibitors (PIs). Included amongst these is direct induction of apoptosis through c-Jun NH2-terminal kinase (JNK) and p53. The expression of p53, a known tumor-suppressor important in activating cell death under diverse circumstances, is induced by treatment with PIs, which can induce apoptosis even in the presence of mutant p53.
Since Proteasome Inhibitors have been impressively effective in the treatment of hematologic malignancies, they continue to be an area of interest for new indications and to improve existing PI regimens. Clinical trials of PIs in combination with other agents are being conducted in leukemias, lymphomas, solid tumors and GVHD. PIs continue to be developed that might target the proteasome at different sites to overcome resistance or have activity in different malignancies. Areas of resistance include hyperactivation of the trypsin-like (?2) and caspase-like (?1) proteolytic sites to compensate for inactivation at the chymotrypsin-like (?5) site. Proteasome Inhibitors target cellular mechanisms of protein degradation by blocking the ? proteolytic subunits of the 20s proteasome.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Proteasome Inhibitors R&D. The therapies under development are focused on novel approaches for Proteasome Inhibitors.
This segment of the Proteasome Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Proteasome Inhibitors Emerging Drugs
- Marizomib: Celgene
It is currently in Phase III stage of development and is being developed by Celgene.
- Carfilzomib: Amgen
Further product details are provided in the report……..
Proteasome Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Proteasome Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Proteasome Inhibitors
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Proteasome Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Proteasome Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Proteasome Inhibitors drugs.
Proteasome Inhibitors Report Insights
- Proteasome Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Proteasome Inhibitors drugs?
- How many Proteasome Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Proteasome Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Proteasome Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Proteasome Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Kezar Life Sciences
- Amgen
- Celgene
- Cantex Pharmaceuticals
- Takeda
- Principia Biopharma
- KZR 616
- Carfilzomib
- Marizomib
- Dicopp
- TAK-169
- Research programme: Proteasome Inhibitors
Introduction
Executive Summary
Proteasome Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Proteasome Inhibitors– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Proteasome Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Proteasome Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Marizomib: Celgene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
KZR 616: Kezar Life Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
TAK-169: Takeda
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Research programme: Proteasome Inhibitors: Principia Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Proteasome Inhibitors Key Companies
Proteasome Inhibitors Key Products
Proteasome Inhibitors- Unmet Needs
Proteasome Inhibitors- Market Drivers and Barriers
Proteasome Inhibitors- Future Perspectives and Conclusion
Proteasome Inhibitors Analyst Views
Proteasome Inhibitors Key Companies
Appendix
Executive Summary
Proteasome Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Proteasome Inhibitors– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Proteasome Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Proteasome Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Marizomib: Celgene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
KZR 616: Kezar Life Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
TAK-169: Takeda
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Research programme: Proteasome Inhibitors: Principia Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Proteasome Inhibitors Key Companies
Proteasome Inhibitors Key Products
Proteasome Inhibitors- Unmet Needs
Proteasome Inhibitors- Market Drivers and Barriers
Proteasome Inhibitors- Future Perspectives and Conclusion
Proteasome Inhibitors Analyst Views
Proteasome Inhibitors Key Companies
Appendix
